Fennec Pharmaceuticals (FENC) Total Non-Current Liabilities (2010 - 2025)

Fennec Pharmaceuticals' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $24.6 million for Q4 2025.

• Quarterly Total Non-Current Liabilities fell 44.05% year-over-year to $24.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.6 million (down 44.05% YoY) and the FY2025 annual result came in at $24.6 million, down 44.05% from the prior year.
• Total Non-Current Liabilities was $24.6 million for Q4 2025 at Fennec Pharmaceuticals, down from $43.9 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $56.8 million in Q2 2024 and bottomed at $4.0 million in Q2 2022.
• A 5-year average of $29.0 million and a median of $25.4 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities soared 536.24% — and 2025, when it sank 44.05%.
• Fennec Pharmaceuticals' Total Non-Current Liabilities stood at $5.0 million in 2021, then surged by 399.18% to $24.9 million in 2022, then increased by 24.23% to $30.9 million in 2023, then surged by 41.92% to $43.9 million in 2024, then sank by 44.05% to $24.6 million in 2025.
• Business Quant data shows FENC's Total Non-Current Liabilities at $24.6 million in Q4 2025, $43.9 million in Q3 2025, and $43.9 million in Q2 2025.